EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

EMA authorised Obodence (denosumab) by Samsung Bioepis NL B.V. for osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Obodence (denosumab)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal;Osteoporosis;Bone Resorption. MAH: Samsung Bioepis NL B.V.. Decision date: 05/01/2026